Research programme: sigma receptor modulators - Anavex Life Sciences

Drug Profile

Research programme: sigma receptor modulators - Anavex Life Sciences

Alternative Names: ANAVEX 1005; ANAVEX 1007; ANAVEX 1067; ANAVEX 1079; ANAVEX 1519; ANAVEX 27-1041; ANAVEX 28-1078; ANAVEX 30-1022; ANAVEX 35-3016; ANAVEX 40-1042; ANAVEX 7-1037; ANAVEX 8-142; ANAVEX™ 1066; Cancer therapeutics - Anavex Life Sciences; Sigmaceptor-C™ programme

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anavex Life Sciences
  • Class Analgesics; Antineoplastics; Small molecules
  • Mechanism of Action Chloride channel modulators; Muscarinic M3 receptor antagonists; Sigma-1 receptor agonists; Sigma-1 receptor antagonists; Sigma-2 receptor agonists; Sigma-2 receptor antagonists; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuropathic pain; Ovarian cancer; Pain; Pancreatic cancer
  • No development reported Acute pain; Malignant melanoma; Prostate cancer; Solid tumours

Most Recent Events

  • 25 Jan 2018 Sigma receptor modulators (ANAVEX 1066) is still in preclinical development for Visceral pain, Pancreatic cancer and neuropathic pain (Anavex Life Sciences pipeline, January 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute pain in Switzerland
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top